{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:40:11Z","timestamp":1791510011344,"version":"4.3.4"},"reference-count":52,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Psoriasis is a chronic autoimmune disease that significantly impairs patients\u2019 quality of life. With the growing availability of biologic drugs \u2013 each varying in efficacy, safety, dosing, and cost \u2013 treatment decisions have become increasingly complex. A study conducted from March to July 2024 surveyed 302 Vietnamese patients with moderate to severe psoriasis to assess preferences for biologic therapies. Using a discrete choice experiment (DCE), participants evaluated 6 treatment attributes: short-term efficacy, long-term efficacy, sustained efficacy after drug withdrawal, frequency of administration, copayment, and risk of serious infection. Preference data were analysed using conditional logit models. Analysis revealed that treatment cost (relative importance [RI]: 31.4%) and long-term efficacy (RI: 25.3%) were\u00a0the most critical factors influencing patient decisions,\u00a0while sustained efficacy after withdrawal and early onset of efficacy were less impactful. Long-term efficacy and cost consistently ranked highest across all patient subgroups, with variations depending on demographic and clinical characteristics. These findings provide practical guidance for clinicians to incorporate patient preferences into the selection of biologic therapies, with particular emphasis on treatment cost and long-term efficacy. The significant influence of treatment cost also highlights the need for healthcare policymakers in Vietnam to enhance reimbursement policies and financial support programmes, improving access and equity in psoriasis care.<\/jats:p>","DOI":"10.2340\/actadv.v105.42840","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:58:16Z","timestamp":1746683896000},"page":"adv42840","source":"Crossref","is-referenced-by-count":1,"title":["Patient-centred Preferences for Biologic Therapies in Moderate to Severe Psoriasis in Vietnam: A Discrete Choice Experiment"],"prefix":"10.2340","volume":"105","author":[{"given":"Chuyen Thi Hong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Thi Mai Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung","family":"The Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"110254","doi-asserted-by":"crossref","unstructured":"Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol 2022; 13: 880201.","DOI":"10.3389\/fimmu.2022.880201"},{"key":"110255","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2022.880201","DOI":"10.3389\/fimmu.2022.880201"},{"key":"110256","doi-asserted-by":"crossref","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study. Front Med (Lausanne) 2021; 8: 743180.","DOI":"10.3389\/fmed.2021.743180"},{"key":"110257","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2021.743180","DOI":"10.3389\/fmed.2021.743180"},{"key":"110258","doi-asserted-by":"crossref","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, -Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.","DOI":"10.1136\/bmj.m1590"},{"key":"110259","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.m1590","DOI":"10.1136\/bmj.m1590"},{"key":"110260","doi-asserted-by":"crossref","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet 2015; 386: 983\u2013994.","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"110261","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s0140-6736(14)61909-7","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"110262","doi-asserted-by":"crossref","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl 2: ii18\u201323; discussion ii24\u201325.","DOI":"10.1136\/ard.2004.033217"},{"key":"110263","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/ard.2004.033217","DOI":"10.1136\/ard.2004.033217"},{"key":"110264","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021; 35: 281\u2013317.","DOI":"10.1111\/jdv.16926"},{"key":"110265","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16926","DOI":"10.1111\/jdv.16926"},{"key":"110266","doi-asserted-by":"crossref","unstructured":"Smith CH, Yiu ZZN, Bale T, Burden AD, Coates Laura C, Eckert E, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update. Br Jo Dermatol 2023; 190: 270\u2013272.","DOI":"10.1093\/bjd\/ljad347"},{"key":"110267","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljad347","DOI":"10.1093\/bjd\/ljad347"},{"key":"110268","doi-asserted-by":"crossref","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 2024; 83: 706\u2013719.","DOI":"10.1136\/ard-2024-225534"},{"key":"110269","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/ard-2024-225531","DOI":"10.1136\/ard-2024-225531"},{"key":"110270","doi-asserted-by":"crossref","unstructured":"Lecluse LL, Tutein Nolthenius JL, Bos JD, Spuls PI. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009; 160: 1340\u20131343.","DOI":"10.1111\/j.1365-2133.2009.09115.x"},{"key":"110271","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09115.x","DOI":"10.1111\/j.1365-2133.2009.09115.x"},{"key":"110272","doi-asserted-by":"crossref","unstructured":"Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Sch\u00f6llgen I, Terris DD. Matching physicians\u2019 treatment recommendations to patients\u2019 treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 2013; 27: 763\u2013770.","DOI":"10.1111\/j.1468-3083.2012.04569.x"},{"key":"110273","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04569.x","DOI":"10.1111\/j.1468-3083.2012.04569.x"},{"key":"110274","doi-asserted-by":"crossref","unstructured":"Tsai T-F, Ho J-C, Chen Y-J, Hsiao P-F, Lee W-R, Chi C-C, et al. Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan. Dermatologica Sinica 2018; 36: 190\u2013195.","DOI":"10.1016\/j.dsi.2018.06.006"},{"key":"110275","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.dsi.2018.06.006","DOI":"10.1016\/j.dsi.2018.06.006"},{"key":"110276","doi-asserted-by":"crossref","unstructured":"Umar N, Litaker D, Schaarschmidt ML, Peitsch WK, Schmieder A, Terris DD. Outcomes associated with matching patients\u2019 treatment preferences to physicians\u2019 recommendations: study methodology. BMC Health Serv Res 2012; 12: 1.","DOI":"10.1186\/1472-6963-12-1"},{"key":"110277","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1472-6963-12-1","DOI":"10.1186\/1472-6963-12-1"},{"key":"110278","doi-asserted-by":"crossref","unstructured":"Nguyen HT, Pham NTU, Tran TNA, Pham NN, Bui YT, Vu TTP. Long-term effectiveness and drug survival of secukinumab in Vietnamese patients with psoriasis: results from a retrospective ENHANCE Study. Dermatol Ther (Heidelb) 2023; 13: 465\u2013476.","DOI":"10.1007\/s13555-022-00867-y"},{"key":"110279","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-022-00867-y","DOI":"10.1007\/s13555-022-00867-y"},{"key":"110280","doi-asserted-by":"crossref","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 2014; 32: 883\u2013902.","DOI":"10.1007\/s40273-014-0170-x"},{"key":"110281","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40273-014-0170-x","DOI":"10.1007\/s40273-014-0170-x"},{"key":"110282","doi-asserted-by":"crossref","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health \u2013 a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011; 14: 403\u2013413.","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"110283","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jval.2010.11.013","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"110284","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461\u20132498.","DOI":"10.1111\/jdv.16915"},{"key":"110285","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16915","DOI":"10.1111\/jdv.16915"},{"key":"110286","doi-asserted-by":"crossref","unstructured":"Johnson FR, Ozdemir S, Phillips KA. Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys. Soc Sci Med 2010; 70: 183\u2013190.","DOI":"10.1016\/j.socscimed.2009.10.021"},{"key":"110287","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.socscimed.2009.10.021","DOI":"10.1016\/j.socscimed.2009.10.021"},{"key":"110288","doi-asserted-by":"crossref","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 2013; 16: 3\u201313.","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"110289","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"110290","doi-asserted-by":"crossref","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health 2016; 19: 300\u2013315.","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"110291","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jval.2016.04.004","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"110292","doi-asserted-by":"crossref","unstructured":"Lang Y, Wu B, Sun Z, Ye E, Dou G, Guan X. Patient preference for biologic treatments of psoriasis in the Chinese setting. Patient Prefer Adherence 2022; 16: 1071\u20131084.","DOI":"10.2147\/PPA.S357795"},{"key":"110293","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/ppa.S357795","DOI":"10.2147\/PPA.S357795"},{"key":"110294","doi-asserted-by":"crossref","unstructured":"Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. J -Dermatol 2019; 46: 466\u2013477.","DOI":"10.1111\/1346-8138.14870"},{"key":"110295","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.14870","DOI":"10.1111\/1346-8138.14870"},{"key":"110296","doi-asserted-by":"crossref","unstructured":"Schaarschmidt ML, Schmieder A, Umar N, Terris D, -Goebeler M, Goerdt S, et al. Patient preferences for psoriasis -treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011; 147: 1285\u20131294.","DOI":"10.1001\/archdermatol.2011.309"},{"key":"110297","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archdermatol.2011.309","DOI":"10.1001\/archdermatol.2011.309"},{"key":"110298","doi-asserted-by":"crossref","unstructured":"Komine M, Kim H, Yi J, Zhong Y, Sakai Y, Crawford B, et al. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan. J Dermatol 2023; 50: 766\u2013777.","DOI":"10.1111\/1346-8138.16746"},{"key":"110299","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.16746","DOI":"10.1111\/1346-8138.16746"},{"key":"110300","doi-asserted-by":"crossref","unstructured":"Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (-Heidelb) 2019; 9: 785\u2013797.","DOI":"10.1007\/s13555-019-00334-1"},{"key":"110301","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-019-00334-1","DOI":"10.1007\/s13555-019-00334-1"},{"key":"110302","doi-asserted-by":"crossref","unstructured":"Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007; 143: 1175\u20131179.","DOI":"10.1001\/archderm.143.9.1175"},{"key":"110303","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.143.9.1175","DOI":"10.1001\/archderm.143.9.1175"},{"key":"110304","doi-asserted-by":"crossref","unstructured":"Bolt T, Kobayashi H, Mahlich J. Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan. Pharmacoecon Open 2019; 3: 255\u2013264.","DOI":"10.1007\/s41669-018-0104-1"},{"key":"110305","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s41669-018-0104-1","DOI":"10.1007\/s41669-018-0104-1"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42840\/50056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42840\/50056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:58:30Z","timestamp":1746683910000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/42840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":52,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.42840","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}